Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Vascular Biogenics

Nasdaq:VBLT
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
VBLT
Nasdaq
$48M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The last earnings update was 9 days ago. More info.


Add to Portfolio Compare Print
  • Vascular Biogenics has significant price volatility in the past 3 months.
VBLT Share Price and Events
7 Day Returns
20.5%
NasdaqGM:VBLT
5.2%
US Biotechs
10.5%
US Market
1 Year Returns
-13.2%
NasdaqGM:VBLT
0%
US Biotechs
-11.5%
US Market
VBLT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Vascular Biogenics (VBLT) 20.5% -0.8% 16.8% -13.2% -76% -72.3%
US Biotechs 5.2% -6.5% -8.7% 0% 6.2% -10.4%
US Market 10.5% -15.4% -21.4% -11.5% 5.4% 18.1%
1 Year Return vs Industry and Market
  • VBLT underperformed the Biotechs industry which returned 0% over the past year.
  • VBLT underperformed the Market in United States of America which returned -11.5% over the past year.
Price Volatility
VBLT
Industry
5yr Volatility vs Market

Value

 Is Vascular Biogenics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Vascular Biogenics. This is due to cash flow or dividend data being unavailable. The share price is $1.32.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Vascular Biogenics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Vascular Biogenics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:VBLT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-0.54
NasdaqGM:VBLT Share Price ** NasdaqGM (2020-03-27) in USD $1.32
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.4x
United States of America Market PE Ratio Median Figure of 2,939 Publicly-Listed Companies 12.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Vascular Biogenics.

NasdaqGM:VBLT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:VBLT Share Price ÷ EPS (both in USD)

= 1.32 ÷ -0.54

-2.43x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vascular Biogenics is loss making, we can't compare its value to the US Biotechs industry average.
  • Vascular Biogenics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Vascular Biogenics's expected growth come at a high price?
Raw Data
NasdaqGM:VBLT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.43x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
1.7%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.96x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Vascular Biogenics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Vascular Biogenics's assets?
Raw Data
NasdaqGM:VBLT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $1.00
NasdaqGM:VBLT Share Price * NasdaqGM (2020-03-27) in USD $1.32
United States of America Biotechs Industry PB Ratio Median Figure of 429 Publicly-Listed Biotechs Companies 2.53x
United States of America Market PB Ratio Median Figure of 5,148 Publicly-Listed Companies 1.26x
NasdaqGM:VBLT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:VBLT Share Price ÷ Book Value per Share (both in USD)

= 1.32 ÷ 1.00

1.32x

* Primary Listing of Vascular Biogenics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vascular Biogenics is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Vascular Biogenics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Vascular Biogenics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Vascular Biogenics expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
1.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Vascular Biogenics expected to grow at an attractive rate?
  • Unable to compare Vascular Biogenics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Vascular Biogenics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Vascular Biogenics's revenues are expected to decrease over the next 1-3 years, this is below the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:VBLT Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:VBLT Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 1.7%
NasdaqGM:VBLT Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts -6.7%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:VBLT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:VBLT Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 -6
2023-12-31 -24
2022-12-31 -41
2021-12-31 0 -30 2
2020-12-31 1 -25 4
2020-03-28
NasdaqGM:VBLT Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 1 -13 -19
2019-09-30 1 -12 -18
2019-06-30 1 -13 -18
2019-03-31 1 -15 -17
2018-12-31 1 -16 -20
2018-09-30 14 -2 -10
2018-06-30 14 -1 -11
2018-03-31 14 -2 -12
2017-12-31 14 -4 -10
2017-09-30 -18 -21
2017-06-30 -17 -18
2017-03-31 -15 -16

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Vascular Biogenics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Vascular Biogenics's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:VBLT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Vascular Biogenics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:VBLT Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -0.07 -0.07 -0.07 1.00
2023-12-31 -0.35 -0.35 -0.35 1.00
2022-12-31 -0.70 -0.70 -0.70 1.00
2021-12-31 -0.72 -0.68 -0.76 3.00
2020-12-31 -0.68 -0.63 -0.75 4.00
2020-03-28
NasdaqGM:VBLT Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -0.54
2019-09-30 -0.49
2019-06-30 -0.50
2019-03-31 -0.51
2018-12-31 -0.62
2018-09-30 -0.33
2018-06-30 -0.40
2018-03-31 -0.44
2017-12-31 -0.37
2017-09-30 -0.79
2017-06-30 -0.66
2017-03-31 -0.63

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Vascular Biogenics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Vascular Biogenics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Vascular Biogenics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Vascular Biogenics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Vascular Biogenics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Vascular Biogenics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Vascular Biogenics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Vascular Biogenics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Vascular Biogenics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Vascular Biogenics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:VBLT Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 0.56 -19.46 4.94 15.47
2019-09-30 0.58 -17.60 4.74 15.48
2019-06-30 0.60 -18.10 5.06 16.02
2019-03-31 0.64 -17.46 5.24 14.39
2018-12-31 0.59 -20.46 5.62 15.94
2018-09-30 14.31 -10.28 6.23 16.96
2018-06-30 14.21 -11.47 6.40 17.37
2018-03-31 14.03 -12.28 6.93 18.49
2017-12-31 13.86 -10.14 6.41 17.77
2017-09-30 -21.25 5.56 16.09
2017-06-30 -17.91 4.91 13.57
2017-03-31 -16.31 4.07 12.59
2016-12-31 -16.00 3.83 12.45
2016-09-30 -14.36 3.96 10.68
2016-06-30 -16.95 3.66 13.41
2016-03-31 -16.64 3.74 13.17
2015-12-31 -14.89 3.67 11.20
2015-09-30 -16.86 2.78 11.68
2015-06-30 -14.59 2.44 9.68
2015-03-31 -15.33 1.78 10.66
2014-12-31 -17.41 1.56 10.97
2014-09-30 -17.68 2.31 12.25
2013-12-31 -17.37 2.45 13.51

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Vascular Biogenics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Vascular Biogenics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Vascular Biogenics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Vascular Biogenics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Vascular Biogenics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Vascular Biogenics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Vascular Biogenics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Vascular Biogenics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Vascular Biogenics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Vascular Biogenics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Vascular Biogenics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Vascular Biogenics Company Filings, last reported 2 months ago.

NasdaqGM:VBLT Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 35.84 0.00 36.54
2019-09-30 41.16 0.00 40.55
2019-06-30 45.49 0.00 45.14
2019-03-31 49.59 0.00 47.66
2018-12-31 53.09 0.00 50.48
2018-09-30 56.63 0.00 53.72
2018-06-30 61.06 0.00 58.53
2018-03-31 50.34 0.00 49.89
2017-12-31 55.90 0.00 54.73
2017-09-30 30.04 0.00 28.16
2017-06-30 35.10 0.00 33.79
2017-03-31 38.12 0.00 39.63
2016-12-31 42.40 0.00 45.25
2016-09-30 46.61 0.00 48.88
2016-06-30 49.49 0.00 51.58
2016-03-31 30.53 0.00 33.19
2015-12-31 35.01 0.00 37.15
2015-09-30 23.95 0.00 27.64
2015-06-30 29.60 0.00 31.55
2015-03-31 32.36 0.00 34.39
2014-12-31 35.10 0.00 36.78
2014-09-30 3.04 0.00 4.78
2013-12-31 -23.58 31.04 10.87
  • Vascular Biogenics has no debt.
  • Vascular Biogenics currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Vascular Biogenics has sufficient cash runway for 2.9 years based on current free cash flow.
  • Vascular Biogenics has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of -1.3% each year.
X
Financial health checks
We assess Vascular Biogenics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Vascular Biogenics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Vascular Biogenics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Vascular Biogenics dividends.
If you bought $2,000 of Vascular Biogenics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Vascular Biogenics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Vascular Biogenics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:VBLT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1949 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:VBLT Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Vascular Biogenics has not reported any payouts.
  • Unable to verify if Vascular Biogenics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Vascular Biogenics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Vascular Biogenics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Vascular Biogenics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Vascular Biogenics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Vascular Biogenics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Vascular Biogenics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Dror Harats
COMPENSATION $3,049,000
AGE 62
TENURE AS CEO 20.2 years
CEO Bio

Prof. Dror Harats, MD has been the Chief Executive Officer of Vascular Biogenics Ltd., since 2000. Prof. Harats founded VBL in 2000 based on over 20 years of research in Atherosclerosis, Vascular Biology and Lipid Metabolism. Prof. Harats is the Chairman of Bert W Strassburger Lipid Centre Review Board and its Director at Chaim Sheba Medical Centre - Tel Hashomer. He has been a Director of Vascular Biogenics Ltd. since January 2001. He consulted to major Pharmaceutical Companies. He is also a Professor of Medicine in the Departments of Internal Medicine and Biochemistry at the Sackler Faculty of Medicine of Tel-Aviv University. Prof. Harats received MD from Hadassah Medical School at the Hebrew University of Jerusalem, Israel and has carried out Post-Doctoral work at University of California, San Francisco.

CEO Compensation
  • Dror's compensation has increased whilst company is loss making.
  • Dror's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Vascular Biogenics management team in years:

14.2
Average Tenure
56
Average Age
  • The average tenure for the Vascular Biogenics management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Dror Harats

TITLE
CEO & Director
COMPENSATION
$3M
AGE
62
TENURE
20.2 yrs

Amos Ron

TITLE
CFO & Company Secretary
COMPENSATION
$2M
AGE
64
TENURE
8.8 yrs

Erez Feige

TITLE
Vice President of Business Operations
COMPENSATION
$1M
AGE
45
TENURE
6.2 yrs

Eyal Breitbart

TITLE
Vice President of Research & Operations
COMPENSATION
$2M
AGE
52
TENURE
14.2 yrs

Naamit Sher

TITLE
Vice President of Drug Development & Regulatory Affairs
COMPENSATION
$1M
AGE
65
TENURE
14.2 yrs

Ayelet Horn

TITLE
General Counsel
AGE
48
TENURE
20.2 yrs

Deborah Scott

TITLE
Managing Director of Financial Communications

Yael Cohen

TITLE
Medical Director
COMPENSATION
$982K
AGE
56
TENURE
12.2 yrs
Board of Directors Tenure

Average tenure and age of the Vascular Biogenics board of directors in years:

11.3
Average Tenure
65.5
Average Age
  • The average tenure for the Vascular Biogenics board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Ben Shapiro

TITLE
Chairman
AGE
79
TENURE
13.2 yrs

Dror Harats

TITLE
CEO & Director
COMPENSATION
$3M
AGE
62
TENURE
19.2 yrs

Susan Kelley

TITLE
Non-Executive Director & Head of Scientific Advisory Board
AGE
64
TENURE
0.1 yrs

Dave Hastings

TITLE
Non-Executive Director
AGE
58
TENURE
2.2 yrs

Ruth Arnon

TITLE
Non-Executive Director
AGE
86
TENURE
12.6 yrs

Ruti Alon

TITLE
Non-Executive Director
AGE
67
TENURE
10 yrs

Keith Bible

TITLE
Member of Scientific Advisory Board

Patrick Wen

TITLE
Member of Scientific Advisory Board

Bonnie Goldman

TITLE
Member of Scientific Advisory Board

Andrew Brenner

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Vascular Biogenics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Vascular Biogenics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Do Directors Own Vascular Biogenics Ltd. (NASDAQ:VBLT) Shares?

Taking a look at our data on the ownership groups (below), it's seems that institutional investors have bought into the company. … View our latest analysis for Vascular Biogenics NasdaqGM:VBLT Ownership Summary, July 18th 2019 What Does The Institutional Ownership Tell Us About Vascular Biogenics? … We can see that Vascular Biogenics does have institutional investors; and they hold 13% of the stock.

Simply Wall St -

If You Had Bought Vascular Biogenics (NASDAQ:VBLT) Stock Three Years Ago, You'd Be Sitting On A 56% Loss, Today

While not a mind-blowing move, it is good to see that the Vascular Biogenics Ltd. … When it last reported its balance sheet in December 2018, Vascular Biogenics had net cash of US$43m. … With the share price down 24% per year, over 3 years, it seems likely that the need for cash is weighing on investors' minds.

Simply Wall St -

Could The Vascular Biogenics Ltd. (NASDAQ:VBLT) Ownership Structure Tell Us Something Useful?

If you want to know who really controls Vascular Biogenics Ltd. … Generally speaking, as a company grows, institutions will increase their ownership. … With a market capitalization of US$48m, Vascular Biogenics is a small cap stock, so it might not be well known by many institutional investors.

Simply Wall St -

Vascular Biogenics Ltd (NASDAQ:VBLT) Insiders Increased Their Holdings

So shareholders might well want to know whether insiders have been buying or selling shares in Vascular Biogenics Ltd (NASDAQ:VBLT). … Vascular Biogenics Insider Transactions Over The Last Year. … In the last twelve months, the biggest single purchase by an insider was when Thai Lee bought US$950k worth of shares at a price of US$6.40 per share.

Simply Wall St -

Who Are The Major Shareholders In Vascular Biogenics Ltd (NASDAQ:VBLT)?

A look at the shareholders of Vascular Biogenics Ltd (NASDAQ:VBLT) can tell us which group is most powerful. … With a market capitalization of US$56m, Vascular Biogenics is a small cap stock, so it might not be well known by many institutional investors. … See our latest analysis for Vascular Biogenics

Simply Wall St -

Vascular Biogenics Ltd's (NASDAQ:VBLT) Path To Profitability

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. … The US$80.72m market-cap posted a loss in its most recent financial year of -US$10.14m and a latest trailing-twelve-month loss of -US$12.28m leading to an even wider gap between loss and breakeven … Many investors are wondering the rate at which VBLT will turn a profit, with the big question being “when will the company breakeven?”

Simply Wall St -

Why Vascular Biogenics Ltd's (NASDAQ:VBLT) Investor Composition Impacts Your Returns

With this size of ownership, retail investors can collectively play a role in major company policies that affect shareholders returns, including executive remuneration and the appointment of directors. … Private Company Ownership Potential investors in VBLT should also look at another important group of investors: private companies, with a stake of 2.48%, who are primarily invested because of strategic and capital gain interests. … Thus, investors not need worry too much about the consequences of these holdings.What this means for you: Institutional ownership level and composition in VBLT is not high nor active enough to significantly impact its investment thesis.

Simply Wall St -

Vascular Biogenics Ltd (VBLT): Is Now The Time To Bet On Healthcare?

Today, I will analyse the industry outlook, and also determine whether VBLT is a laggard or leader relative to its healthcare sector peers. … As a future industry laggard in growth, VBLT may be a cheaper stock relative to its peers. … VBLT is a biotech industry laggard in terms of its future growth outlook.

Simply Wall St -

How Much is Vascular Biogenics Ltd's (VBLT) CEO Getting Paid?

In the past year, VBLT released negative earnings of -$18M , which is a further decline from prior year's loss of -$17M. … During times of negative earnings, the company may be incurring a period of reinvestment and growth, or it can be a sign of some headwind. … Typically I would look at market cap and earnings as a proxy for performance, however, VBLT's negative earnings lower the usefulness of my formula.

Simply Wall St -

Company Info

Description

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company’s program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and in Phase III clinical trials for recurrent platinum-resistant ovarian cancer, as well as for Phase II clinical trials for iodine-resistant differentiated thyroid cancer. The company is also developing VB-111, which is in Phase I clinical trials for the treatment of patients with various types of advanced metastatic cancer types, including thyroid cancer, neuroendocrine cancer, renal cell carcinoma, and lung cancer. In addition, it is developing VB-511, an anti-angiogenic candidate for oncology; VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases; VB-201, a Lecinoxoid-based compound for the control of chronic inflammatory disorders; and VB-600 that is in pre-clinical stage for targeting of MOSPD2 for immuno-oncology and anti-inflammatory applications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Modi’in, Israel.

Details
Name: Vascular Biogenics Ltd.
VBLT
Exchange: NasdaqGM
Founded: 2000
$47,716,334
36,148,738
Website: http://www.vblrx.com
Address: Vascular Biogenics Ltd.
8 HaSatat Street,
Modi’in,
78106,
Israel
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM VBLT Ordinary Shares Nasdaq Global Market US USD 01. Oct 2014
Number of employees
Current staff
Staff numbers
38
Vascular Biogenics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 04:49
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/27
Last earnings filing: 2020/03/19
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.